BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10102972)

  • 1. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
    Gionchetti P; Ardizzone S; Benvenuti ME; Bianchi Porro G; Biasco G; Cesari P; D'albasio G; De Franchis R; Monteleone G; Pallone F; Ranzi T; Trallori G; Valpiani D; Vecchi M; Campieri M
    Aliment Pharmacol Ther; 1999 Mar; 13(3):381-8. PubMed ID: 10102972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
    Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
    Lee FI; Jewell DP; Mani V; Keighley MR; Kingston RD; Record CO; Grace RH; Daniels S; Patterson J; Smith K
    Gut; 1996 Feb; 38(2):229-33. PubMed ID: 8801202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.
    Malchow H; Gertz B;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):415-23. PubMed ID: 11876694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB; Wedel MK; Xia S; Baker BF
    Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
    Hartmann F; Stein J;
    Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
    Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
    Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
    Rufle W; Frühmorgen P; Huber W; Kimmig JM
    Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
    Paoluzi P; D'Albasio G; Pera A; Bianchi Porro G; Paoluzi OA; Pica R; Cottone M; Miglioli M; Prantera C; Sturniolo G; Ardizzone S
    Dig Liver Dis; 2002 Nov; 34(11):787-93. PubMed ID: 12546514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
    Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
    Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
    Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
    Gionchetti P; Venturi A; Rizzello F; Corbelli C; Fanti S; Ferretti M; Boschi S; Miglioli M; Campieri M
    Aliment Pharmacol Ther; 1997 Aug; 11(4):679-84. PubMed ID: 9305475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.